Biodexa Pharmaceuticals Plc
BDRX
$1.55
-$0.01-0.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -90.71% | -83.71% | -61.08% | -46.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -90.71% | -83.71% | -61.08% | -46.41% |
| Cost of Revenue | 37.77% | 9.08% | -15.16% | -16.20% | -19.89% |
| Gross Profit | -51.96% | -20.28% | 6.91% | 9.89% | 15.60% |
| SG&A Expenses | 29.01% | -26.38% | -41.54% | -36.11% | -32.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -127.84% | -133.06% | -151.43% | -2.92% | 36.69% |
| Total Operating Expenses | 33.85% | -9.07% | -28.50% | -25.91% | -25.81% |
| Operating Income | -41.44% | 4.79% | 25.38% | 23.53% | 24.16% |
| Income Before Tax | 18.02% | 17.81% | 17.19% | 12.62% | 10.53% |
| Income Tax Expenses | 36.51% | 56.60% | 67.34% | 57.93% | 50.67% |
| Earnings from Continuing Operations | 16.97% | 14.81% | 12.40% | 8.00% | 6.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.97% | 14.81% | 12.40% | 8.00% | 6.16% |
| EBIT | -41.44% | 4.79% | 25.38% | 23.53% | 24.16% |
| EBITDA | -42.70% | 4.71% | 25.72% | 23.77% | 24.28% |
| EPS Basic | 78.87% | -34.36% | -- | -- | -- |
| Normalized Basic EPS | 66.68% | -55.18% | -- | -- | -- |
| EPS Diluted | 78.87% | -34.36% | -- | -- | -- |
| Normalized Diluted EPS | 66.68% | -55.18% | -- | -- | -- |
| Average Basic Shares Outstanding | 1,758.54% | 2,474.11% | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |